Having a great time at #AAIC2024! 🧠 Day two is over and the conference is filled with valuable insights and exciting connections. And we haven't left yet. Will you be attending #AAIC in the coming few days? Then come discover icobrain aria, our #AI-based software designed for automatic detection and quantification of ARIA-E and ARIA-H. We would be happy to discus on how we can support your clinical practice in treating people living with Alzheimer's disease. Together, let's make a difference in the future of #Alzheimer's care! 🤝
About us
Transforming patient care through imaging AI. Founded in 2011, icometrix (Leuven, Belgium; Boston, USA) strives for data-driven insights and personalized patient care, supported by artificial intelligence. icometrix offers a portfolio of AI solutions to assist healthcare with various challenges; icobrain extracts data from brain MRI and CT scans for the radiological reporting and clinical management of neurological disorders such as multiple sclerosis, brain trauma, epilepsy, stroke, dementia, and Alzheimer's disease. icompanion, a digital platform, and the mobile app helps people with MS and their care team to monitor clinical symptoms and treatments efficiently and objectively. icolung addresses the COVID-19 pandemic by measuring lung involvement on chest CT. Today, icometrix is internationally active and integrated into more than 300 clinical practices. In addition, icometrix collaborates with healthcare providers and pharmaceutical companies on the evaluation of drug research for neurological disorders.
- Website
-
https://icometrix.com
External link for icometrix
- Industry
- Hospitals and Health Care
- Company size
- 51-200 employees
- Headquarters
- Leuven
- Type
- Public Company
- Founded
- 2011
- Specialties
- Multiple Sclerosis, clinical trial imaging, imaging biomarkers, quantitative imaging, advanced imaging, Alzheimer's disease, Epilepsy, Stroke, Traumatic Brain Injury, brain MRI biomarkers, MRI, CT, AI, volumetrics, dementia, neuroradiology, radiology, neurology, and brain
Locations
-
Primary
Kolonel Begaultlaan 1b / 12
Leuven, 3000, BE
-
Boston, MA 02109, US
Employees at icometrix
Updates
-
The field of #Alzheimer's treatment is rapidly changing, is your clinical practice ready? 🧠 Join us at #AAIC to discover icobrain aria, the latest development of icometrix, using our deep learning algorithms to detect ARIA-E and ARIA-H. Find our team at booth #738. 💬 We will be there to answer all your questions and discuss how we can support your clinical practice in the treatment of people living with Alzheimer's disease. See you there! 👋 #AAIC24 #AAIC2024 #icobrain #ad #alzheimersdisease #neurology #radiology #neuroradiology #healthcare #ai
🎥 #Donanemab receives FDA clearance 🚀 But what now? What will be the impact of the increased number of safety scans and the difficulty of diagnosing ARIA? Most of you will probably already have read the news about the FDA approval of Eli Lilly and Company’s #Kisunla (#Donanemab) for early symptomatic stages of Alzheimer’s disease. Clinical trials have shown a significant 35% reduction in cognitive decline over 1.5 years with this innovative therapy. However, the treatment is associated with an increased rate of Amyloid-Related Imaging Abnormalities (#ARIA), which presents both challenges and opportunities for improved diagnostic and therapy strategies. 🎥 In this video, our CTO Dirk Smeets explains these challenges and presents #icobrain aria, the only clinically validated tool for monitoring ARIA-E and ARIA-H. icobrain aria was developed using actual ARIA data and in its validation paper (Sima et al. 2024) icobrain aria showed a significantly improved radiological reader performance for both ARIA-E and ARIA-H 📊 Importantly, icobrain aria is reimbursed once regulatory clearance is obtained, thanks to the CPT codes for icobrain, ensuring that this technology is accessible to those who need it. How do you think AI can further revolutionize Alzheimer’s treatment? Share your thoughts below! 💬 For more info on icobrain aria, check out https://lnkd.in/en_nnafe and leave your email behind to! #neurology #radiology #neuroimaging #AI #healthcareinnovation #alzheimersdisease #alzheimer #dementia #neuroradiology #icometrix #mri
-
For a few years now, our slogan at icometrix has been #BrainHealthMatters 🧠 Clever wordplay aside, this #WorldBrainDay, we want to talk about the growing burden of neurological disorders and the crucial role #medicaltechnology can play 👇 The increasing rate at which neurological disorders are occurring is alarming, affecting millions of lives and putting pressure on healthcare systems and professionals worldwide. Medical technology like #icobrain has proven to help reduce the burden on clinicians and support them in their jobs. However, a clear financial support system is essential, much like the CPT reimbursement code for icobrain in the US 🇺🇸 (read more via the link in comments). Introduced 8 months ago, these CPT codes for icobrain are already making an impact in the US 🇺🇸 #radiology field, enabling clinical sites to access state-of-the-art #icobrain technology that was previously out of reach, or allowing hospitals to roll out the software for all their patients instead of just a subset. The result? More patients receiving the world-class care they deserve. The US reimbursement system, while complex, can serve as an example for the #EU, #Australia, #Canada, #Japan, and others. A unified European legislation could pave the way for more streamlined access to these vital technologies. By working together and advocating for these necessary changes, we can make a real difference in the lives of people living with neurological disorders. Let's continue to strive for a future where brain health is a priority for all. Together, we can make a difference. 🤝 Please repost so we can reach policy makers 🤝 or share your thoughts below! #reimbursement #HealthPolicy #digitalhealth #neurology #worldbrainday #icobrain European Academy of Neurology American Academy of Neurology World Federation Of Neurology
-
-
Attending AAIC2024 in Philadelphia? Don’t miss the chance to connect with this icometrix dreamteam: Wim Van Hecke, Rebecca Bartz, and Kathy Hampton! 🧠 With the news of #donanemab (#kisunla) receiving #FDA clearance, the time is now to come and talk to use about FDA pending icobrain aria, our #AI based software designed for the Automated Detection and Quantification of Amyloid-related Imaging Abnormalities. 📽 Want to see a short demo of icobrain aria by our CTO Dirk Smeets? Check the link in comments! Join us for an engaging discussion at #AAIC2024 booth #738! See you there! 👋
-
📊 Evaluating the efficacy and safety of disease-modifying treatments in real-world clinical practice is essential to understand how clinical trial results translate to broader patient populations. This recent paper on the real-world assessment of dimethyl fumarate showcases how icometrix can support these critical studies with #icobrain. 📰 Check the link in the comments to dive into the full article! In collaboration with: 👉 Stephen Krieger Myassar Zarif Barbara Bumstead Marijean Buhse Olivia Kaczmarek Jared Srinivasan Nuno Miguel Pedrosa de Barros Diana Sima Annemie Ribbens Wim Van Hecke James Lewin Jason Mendoza, Ph.D. Mark Gudesblatt
-
-
🎥 #Donanemab receives FDA clearance 🚀 But what now? What will be the impact of the increased number of safety scans and the difficulty of diagnosing ARIA? Most of you will probably already have read the news about the FDA approval of Eli Lilly and Company’s #Kisunla (#Donanemab) for early symptomatic stages of Alzheimer’s disease. Clinical trials have shown a significant 35% reduction in cognitive decline over 1.5 years with this innovative therapy. However, the treatment is associated with an increased rate of Amyloid-Related Imaging Abnormalities (#ARIA), which presents both challenges and opportunities for improved diagnostic and therapy strategies. 🎥 In this video, our CTO Dirk Smeets explains these challenges and presents #icobrain aria, the only clinically validated tool for monitoring ARIA-E and ARIA-H. icobrain aria was developed using actual ARIA data and in its validation paper (Sima et al. 2024) icobrain aria showed a significantly improved radiological reader performance for both ARIA-E and ARIA-H 📊 Importantly, icobrain aria is reimbursed once regulatory clearance is obtained, thanks to the CPT codes for icobrain, ensuring that this technology is accessible to those who need it. How do you think AI can further revolutionize Alzheimer’s treatment? Share your thoughts below! 💬 For more info on icobrain aria, check out https://lnkd.in/en_nnafe and leave your email behind to! #neurology #radiology #neuroimaging #AI #healthcareinnovation #alzheimersdisease #alzheimer #dementia #neuroradiology #icometrix #mri
-
icometrix reposted this
Exciting news today! After Aduhelm and Leqembi, Eli Lilly and Company's Kisunla (donanemab) is approved for the treatment of early symptomatic #Alzheimer's Disease. The phase III trial demonstrated it slowed cognitive and functional decline by up to 35% compared to placebo after 1.5 years. Compared to Leqembi, Kisunla has a lower frequency of infusion (monthly instead of biweekly) and is the only medication with evidence to support stopping treatment when amyloid plaques are removed. At the downside, the rates of Amyloid related imaging abnormalities (#ARIA), the most common side effect, are higher. As icometrix, we are committed to support the management of #ARIA with #AI, to reduce the possible negative impact of #ARIA. With synergies of innovative treatments and technology, we improve the lives of many patients.
-
-
EAN is coming to an end! It was amazing to meet our partners and witness the rapidly changing landscape of neurology 🧠. We enjoyed insightful talks on #multiplesclerosis, #dementia, #NMO, #MOGAD, #parkinson and other neurological diseases and we are happy to contribute our own scientific work on the #MS topographical model and the relationship between NfL and imaging biomarkers in the #TREMEND trial. It's not too late to meet us. If you are still in Helsinki, reach out to An Tanghe and Lars Costers to plan a meeting. 🇫🇮
-
-
icometrix reposted this
Join us in Helsinki for two #EAN poster presentions 🚰🩸where we'll present our latest work featuring Stephen Krieger and Michael Barnett on how lesion parenchymal fraction supports the topographical model in MS🚰 and recent work with Tobias Sejbæk, Zsolt Illes, Ronald Antulov, Jason Mendoza, Ph.D. and James Lewin on the associations between NfL levels and imaging biomarkers on #dimethylfumarate🩸 Curious? Join us Saturday at 13.15 - 13.21 in Poster Session 1 Can't make it? Reach out to Lars Costers or An Tanghe to plan a meeting during #EAN2024 👋
-
Join us in Helsinki for two #EAN poster presentions 🚰🩸where we'll present our latest work featuring Stephen Krieger and Michael Barnett on how lesion parenchymal fraction supports the topographical model in MS🚰 and recent work with Tobias Sejbæk, Zsolt Illes, Ronald Antulov, Jason Mendoza, Ph.D. and James Lewin on the associations between NfL levels and imaging biomarkers on #dimethylfumarate🩸 Curious? Join us Saturday at 13.15 - 13.21 in Poster Session 1 Can't make it? Reach out to Lars Costers or An Tanghe to plan a meeting during #EAN2024 👋